Arthur Levin Biography and Net Worth

Director of Stoke Therapeutics

Arthur Levin is a director of Stoke Therapeutics and is a key opinion leader in the RNA therapeutics field who has led teams responsible for the development of many oligonucleotides. He is a founding member of Avidity Biosciences and currently serves as Distinguished Scientist and Strategic Leader for the company. Dr. Levin previously held the position of Chief Scientific Officer at Avidity. Prior to that, he was the Executive Vice President of Research and Development at miRagen Therapeutics and held senior drug development roles at Ionis (formerly Isis) Pharmaceuticals and Santaris Pharma.

Dr. Levin has a combined three decades of experience in all aspects of drug development from discovery through drug registration. He has published more than 60 scientific articles and several of the most cited reviews in the field. Dr. Levin is on the scientific advisory boards of multiple institutions. He received a Ph.D. in toxicology from the University of Rochester and has a bachelor’s degree in biology from Muhlenberg College.

What is Arthur A. Levin's net worth?: The estimated net worth of Arthur A. Levin is at least $139.27 thousand as of March 13th, 2026. Dr. Levin owns 4,237 shares of Stoke Therapeutics stock worth more than $139,270 as of March 18th. This net worth evaluation does not reflect any other assets that Dr. Levin may own. Learn More about Arthur A. Levin's net worth.
How do I contact Arthur A. Levin?: The corporate mailing address for Dr. Levin and other Stoke Therapeutics executives is 45 WIGGINS AVENUE, BEDFORD MA, 01730. Stoke Therapeutics can also be reached via phone at (781) 430-8200 and via email at [email protected]. Learn More on Arthur A. Levin's contact information.
Has Arthur A. Levin been buying or selling shares of Stoke Therapeutics?: In the last ninety days, Arthur A. Levin has sold $22,264.00 in Stoke Therapeutics stock. Most recently, Arthur A. Levin sold 605 shares of the business's stock in a transaction on Friday, March 13th. The shares were sold at an average price of $36.80, for a transaction totalling $22,264.00. Following the completion of the sale, the director now directly owns 4,237 shares of the company's stock, valued at $155,921.60. Learn More on Arthur A. Levin's trading history.
Who are Stoke Therapeutics' active insiders?: Stoke Therapeutics' insider roster includes Jonathan Allan (General Counsel), Edward Kaye (), Edward Kaye (Director), Adrian Krainer (Director), Arthur Levin (Director), Huw Nash (COO), Barry Ticho (Insider), and Arthur Tzianabos (Insider). Learn More on Stoke Therapeutics' active insiders.
Are insiders buying or selling shares of Stoke Therapeutics?: In the last twelve months, insiders at the sold shares 36 times. They sold a total of 352,836 shares worth more than $8,943,543.42. The most recent insider tranaction occured on March, 13th when Director Arthur A Levin sold 605 shares worth more than $22,264.00. Insiders at Stoke Therapeutics own 9.5% of the company. Learn More about insider trades at Stoke Therapeutics.
Information on this page was last updated on 3/13/2026.

Arthur A. Levin Insider Trading History at Stoke Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/13/2026	Sell	605	$36.80	$22,264.00	4,237

Arthur A. Levin Buying and Selling Activity at Stoke Therapeutics

Stoke Therapeutics Company Overview

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Today's Range

Now: $31.33

$31.65

$32.85

50 Day Range

MA: $32.69

$28.70

$38.35

2 Week Range

Now: $31.33

$5.35

$40.22

Volume

35,918 shs

Average Volume

736,667 shs

Market Capitalization

$1.79 billion

P/E Ratio

46.33

Dividend Yield

N/A

Beta

1.07